{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-25-000081","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2025-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.592043+00:00","generated_at":"2026-05-17T07:37:19.662419+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Keros reports KER-065 Phase 1 data: BMD improvements sustained to Day 141","bullets":["Phase 1 trial in healthy males showed no dose-limiting toxicities or serious adverse events.","Whole body BMD improved at Day 85 and was sustained through Day 141 (three months post-last dose).","Lumbar spine BMD increased after three doses and remained elevated through Day 141.","Bone biomarker changes indicated increased formation and reduced resorption, consistent with tissue-level effects.","Data presented at ASBMR 2025 support potential in Duchenne muscular dystrophy and bone disorders."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-25-000081","json":"https://secwatch.observer/filing/0001664710-25-000081.json","markdown":"https://secwatch.observer/filing/0001664710-25-000081.md","text":"https://secwatch.observer/filing/0001664710-25-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000081/0001664710-25-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000081/kros-20250908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:37:19.662419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}